FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered.
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst JP Morgan sees Apellis' Syfovre as a potential $1.5B drug. Empaveli's approval for C3G/IC-MPGN could drive stock growth with a U.S. launch in 2H 2025.
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday Sales of the company's top commercialized product didn't meet expectations.
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales The company is best known for its drug, Syfovre, a treatment for geographic atrophy.
